Accessibility Menu
Cytosorbents logo

Cytosorbents(NASDAQ) CTSO

Current Price$0.37
Market Cap$22.71MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2006)-99%
5 Year-95%
1 Year-65%
1 Month-16%
Cytosorbents last closing stock price
MetricPriceDate
Last closeUSD 0.362026-07-23
Cytosorbents stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.17%USD 0.372026-07-16
1 month-15.76%USD 0.432026-06-23
3 month-42.47%USD 0.632026-04-24
Year to date-43.46%USD 0.642025-12-31
1 year-64.57%USD 1.022025-07-23
3 year-90.23%USD 3.702023-07-24
5 year-95.16%USD 7.462021-07-23
Since inception-99.13%USD 43.752006-08-07

Cytosorbents Financials at a Glance

Market Cap

$22.71MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$37.20M

Net Income (TTM)

-$11.85M

EPS (TTM)

-$0.19

P/E Ratio

-1.89

Dividend

$0.00

Beta (Volatility)

0.88 (Low)

Price

$0.37

Volume

290

Open

$0.40

Previous Close

$0.37

Daily Range

$0.37 - $0.40

52-Week Range

$0.35 - $1.22

Estimated Earnings Date

Aug 6, 2026

CTSO News

rising arrow versus flat arrows

Here's Why Cytosorbents Is Up 17% Today

James BrumleyJul 6, 2021
GettyImages-1138911813

Why CytoSorbents Is Soaring 12% Today

Todd CampbellJul 22, 2020
Man looking at line chart going through floor

Why CytoSorbents Stock Got Clobbered Today

Keith SpeightsJul 21, 2020

Why Cytosorbents Corp Shares Burst Today

Todd CampbellApr 1, 2015

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cytosorbents

Cytosorbents makes devices that clean harmful substances from blood. Its main product helps doctors treat patients with severe infections or during heart surgery. Hospitals use these devices to support patients in critical care situations.

Gadgets That Clean Up: Products and Services

  • DrugSorb-ATR: Device removes blood thinners during surgery; not yet approved in the U.S.
  • VetResQ: Blood purification for animals with severe illness; veterinary market.
  • HemoDefend Platform: Reduces contaminants in donated blood; used in transfusions.
  • Other Pipeline Devices: Includes products for kidney failure, high potassium, and removing contrast agents after scans.

Growth Spurts: Expansion and Strategic Moves

  • Entered European market with CE mark approval for CytoSorb and now sold in more than 70 countries.
  • Expanded direct sales in Germany; built a global distributor network.
  • Launched DrugSorb-ATR regulatory process in the U.S. in September 2024 and in Canada in November 2024.
  • Raised $5.4 million in January 2025 through a rights offering.
  • Reorganized German sales team and added new North American leadership in 2025.

What Makes Cytosorbents Stand Out

Cytosorbents operates globally, with most sales outside the U.S. Its technology works with standard hospital equipment, making adoption easier for clinics. The company focuses on critical care needs where few other solutions exist.

Five Things You Need to Know

  • Q2 2025 revenue was $10 million, up 8.8% from Q2 2024.
  • Germany made up 34.9% of Q2 2025 revenue; U.S. only 0.6%.
  • Gross margin fell to 70.9% in Q2 2025, down from 73.5% a year earlier.
  • Q2 2025 net income was $1.95 million, driven by foreign currency gains.
  • Cash and equivalents were $11.7 million as of June 30, 2025.

Bottom Line

Cytosorbents has built a niche in blood purification for critical care, with most sales in Europe. The company faces ongoing financial and regulatory challenges but continues to adapt its strategy and product lineup.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

129

CEO

Phillip P. Chan, MD, PhD

Website

cytosorbents.com

Headquarters

Princeton, NJ 08540, US

CTSO Financials

Key Financial Metrics (TTM)

Gross Margin

71.01%

Operating Margin

-36.01%

Net Income Margin

-31.85%

Return on Equity

-165.13%

Return on Capital

-40.67%

Return on Assets

-29.21%

Earnings Yield

-52.91%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$22.71MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

62.84M

Volume

290

Avg. Volume

157.36K

Financials (TTM)

Gross Profit

$26.41M

Operating Income

-$13.40M

EBITDA

-$7.78M

Operating Cash Flow

-$10.07M

Capital Expenditure

-$127.76K

Free Cash Flow

-$10.20M

Cash & ST Invst.

$4.81M

Total Debt

$18.96M

Cytosorbents Performance Analysis

Cytosorbents annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 34,688,809-19.6%
20232023-12-31USD 31,084,953-10.4%
20242024-12-31USD 35,594,52014.5%
20252025-12-31USD 37,063,0004.1%
Cytosorbents sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3010.2%
Q32025-09-30-1.4%
Q42025-12-31-2.6%
Q12026-03-31-4.0%
Cytosorbents annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.7532.9%
20232023-12-31USD -0.65-13.0%
20242024-12-31USD -0.38-41.9%
20252025-12-31USD -0.13-65.4%
Cytosorbents sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30219.3%
Q32025-09-30-272.4%
Q42025-12-31-75.0%
Q12026-03-318.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$8.86M

+1.6%

Gross Profit

$6.13M

-1.3%

Gross Margin

69.16%

N/A

Market Cap

$22.71MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$176.06K

N/A

Employees

129

N/A

Net Income

-$5.13M

-246.9%

EBITDA

-$3.90M

-731.6%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$4.81M

-58.5%

Total Debt

$18.96M

-29.7%

Accounts Receivable

$7.15M

-6.8%

Inventory

$4.48M

+48.5%

Long Term Debt

$11.75M

-55.7%

Short Term Debt

$7.21M

+1421.7%

Return on Assets

-29.21%

N/A

Return on Invested Capital

-55.22%

N/A

Free Cash Flow

-$1.17M

+66.6%

Operating Cash Flow

-$1.16M

+66.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NMTCNeuroOne Medical Technologies Corporation
$1.85-4.15%
TELATELA Bio, Inc.
$0.71-2.96%
ICCMIceCure Medical Ltd
$3.23-3.00%
TELOTelomir Pharmaceuticals, Inc. Common Stock
$1.16+9.43%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLATesla
$320.21-0.14%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.76-0.29%
INTCIntel
$100.29-0.02%
NVDANvidia
$208.75-0.02%

Questions About CTSO

What is the current price of Cytosorbents?

Cytosorbents is trading at $0.37 per share.

What is the 52-week range for Cytosorbents?

Over the past 52 weeks, Cytosorbents has traded between $0.35 and $1.22.

How much debt does Cytosorbents have?

As of the most recent reporting period, Cytosorbents reported total debt of $29.54M.

How much cash does Cytosorbents have on hand?

Cytosorbents reported $4.81M in cash and cash equivalents in its most recent financial results.

What is Cytosorbents’s dividend yield?

Cytosorbents does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services